- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer. The PCF Challenge Awards will support a total of 10 scientific projects nationwide; BIDMC is the only institution to receive funding for two projects.
Said PCF executive vice president and chief science officer Howard Soule, PhD, "With reductions in federal funding for prostate cancer research, it's imperative for the PCF to seek the most promising research ideas and fund them with the goal of changing clinical practice and improving outcomes for patients with advanced prostate cancer."
The research team assembled by Sanda, Director of the Prostate Cancer Program at BIDMC and Associate Professor of Surgery/Urology at Harvard Medical School, is combining nanotechnology and cancer immunology expertise in developing a vaccine to treat prostate cancer by boosting patients' immune systems.
"Recent progress has shown that cancer vaccines extend survival for men with prostate cancer and this type of treatment has now been approved by the U.S. Food and Drug Administration," explains Sanda. "However, this first-generation prostate cancer vaccine is exceedingly expensive, and the cumbersome processing of individual patient cells limits availability. Our strategy, which makes use of biodegradable nanoparticles to directly deliver prostate-cancer proteins to the body's requisite immune cells, will stimulate the immune system to directly attack prostate-cancer cells and, therefore, has the potential to be less expensive and more easily disseminated."
Sanda's Prostate Cancer Nanoparticle Vaccine Consortium is co-led by M. Simo Arredouani, PhD, of BIDMC's Department of Surgery; Joseph DeSimone, PhD, of the University of North Carolina Department of Chemistry, and Charles Drake, MD, PhD, of the Johns Hopkins Sidney Kimmell Cancer Center.
"Our work represents a synergistic collaboration that brings together some of the best doctors and scientists in the fields of prostate cancer, nanotechnology, and cancer immunotherapy across three separate leading hospitals," adds Sanda. "Such collaborative team science is the cornerstone for continued progress in developing effective new cancer therapies."
In the second of BIDMC's PCF Challenge Awards, a scientific team led by Steven Balk, MD, PhD, an investigator in BIDMC's Division of Hematology/Oncology and Professor of Medicine at Harvard Medical School, will work on research to identify and exploit mechanisms of response and resistance to therapeutics directed at the androgen receptor pathway.
"We hope to learn why patients invariably become resistant to Abiraterone acetate, a treatment used in advanced prostate-cancer cases following chemotherapy," says Balk. "If we can determine the reasons why this treatment eventually stops working, we will be better equipped to design more effective and targeted therapy for metastatic treatment-resistant disease, the lethal stage of prostate cancer responsible for approximately 30,000 deaths per year."
Co-investigators on the Balk project include BIDMC researchers Glenn Bubley, MD, and Xin Yuan, MD; and Dana-Farber Cancer Institute investigators Toni Choueiri, MD, Phillip Kantoff, MD, Christopher Sweeney, MD and Mary-Ellen Taplin, MD. Co-principal investigators include Peter Nelson, MD, of the University of Washington/Fred Hutchinson Cancer Research Center and Trevor Penning, PhD, of the University of Pennsylvania.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and is ranked third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox.
For more information, please click here
Copyright © NewswiseIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
What makes cancer cells spread? New device offers clues May 19th, 2015
International and U.S. Students and Teachers Headed to Toronto for 34th Annual International Space Development Conference®: Students competed in prestigious NSS-NASA Ames Space Settlement Design Contest May 9th, 2015
Efficiency record for black silicon solar cells jumps to 22.1 percent: Aalto University's researchers improved their previous record by over 3 absolute percents in cooperation with Universitat Politècnica de Catalunya May 18th, 2015
Organic nanoparticles, more lethal to tumors: Carbon-based nanoparticles could be used to sensitize cancerous tumors to proton radiotherapy and induce more focused destruction of cancer cells, a new study shows May 18th, 2015